9-cyclopentyl-2-N-[4-(4-methylpiperidin-1-yl)phenyl]-8-N-phenylpurine-2,8-diamine | 1423290-73-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 9-cyclopentyl-2-N-[4-(4-methylpiperidin-1-yl)phenyl]-8-N-phenylpurine-2,8-diamine
• CAS: 1423290-73-6
• 化学式: C₂₈H₃₃N₇
• 分子量: 467.617
• InChiKey: GWGVAZIXBRLNEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  70.9
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (2-氯-5-硝基-嘧啶-4-基)-环戊基-胺 在 palladium 10% on activated carbon 、 氢气 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 、 正丁醇 为溶剂， 50.0~90.0 ℃ 、101.33 kPa 条件下， 反应 23.0h， 生成 9-cyclopentyl-2-N-[4-(4-methylpiperidin-1-yl)phenyl]-8-N-phenylpurine-2,8-diamine
  参考文献：
  名称：

  Structural Optimization and Structure–Activity Relationships of N²-(4-(4-Methylpiperazin-1-yl)phenyl)-N⁸-phenyl-9H-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations

  摘要：

  This paper describe the structural optimization of a hit compound, N-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.

  DOI：

  10.1021/jm301365e

文献信息

• Structural Optimization and Structure–Activity Relationships of <i>N</i>²-(4-(4-Methylpiperazin-1-yl)phenyl)-<i>N</i>⁸-phenyl-9<i>H</i>-purine-2,8-diamine Derivatives, a New Class of Reversible Kinase Inhibitors Targeting both EGFR-Activating and Resistance Mutations
  作者：Jiao Yang、Li-Jiao Wang、Jing-Jing Liu、Lei Zhong、Ren-Lin Zheng、Yong Xu、Pan Ji、Chun-Hui Zhang、Wen-Jing Wang、Xing-Dong Lin、Lin-Li Li、Yu-Quan Wei、Sheng-Yong Yang

  DOI：10.1021/jm301365e

  日期：2012.12.13

  This paper describe the structural optimization of a hit compound, N-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine (1), which is a reversible kinase inhibitor targeting both EGFR-activating and drug-resistance (T790M) mutations but has poor binding affinity. Structure-activity relationship studies led to the identification of 9-cyclopentyl-N-2-(4-(4-methylpiperazin-1-yl)phenyl)-N-8-phenyl-9H-purine-2,8-diamine (9e) that exhibits significant in vitro antitumor potency against the non-small-cell lung cancer (NSCLC) cell lines HCC827 and H1975, which harbor EGFR-activating and drug-resistance mutations, respectively. Compound 9e was further assessed for potency and selectivity in enzymatic assays and in vivo anti-NSCLC studies. The results indicated that compound 9e is a highly potent kinase inhibitor against both EGFR-activating and resistance mutations and has good kinase spectrum selectivity across the kinome. In vivo, oral administration of compound 9e at a dose of 5 mg/kg caused rapid and complete tumor regression in a HCC827 xenograft model, and an oral dose of 50 mg/kg initiated a considerable antitumor effect in an H1975 xenograft model.